Skip to main content
Caplight Logo









Partner Therapeutics

Partner Therapeutics

Private
Lexington, MassachusettsHealthcare & Life Scienceshttps://www.partnertx.com/

Last Round

Grant

Feb 17, 2022

Total Funding Raised

$100M

Company Overview

Partner Therapeutics is a biopharmaceutical company that develops and commercializes therapies for cancer and other serious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

Leukinesargramostimoncology therapiescancer drugsmedical countermeasuresGM-CSFacute radiation syndromebiodefensechemotherapy supportbone marrow transplant supportacute myeloid leukemiaAMLlate-stage asset acquisitionBARDA contractsNRG1 fusion positive cancerStrategic National Stockpile

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Partner Therapeutics Comparables

Compare Partner Therapeutics with similar companies based on industry and business-model similarity.

Partner Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merus N.V.
85%
Amgen
77%
Teva Pharmaceuticals
76%

Partner Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 17, 2022
GrantAug 4, 2020
Series AFeb 1, 2018

Partner Therapeutics Investors

Notable investors and investment history

Partner Therapeutics investors
InvestorRounds
Perceptive AdvisorsSeries A
U.S. Department of WarGrant
Adams Street PartnersSeries A
MidCap FinancialSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 11, 2025

    Monthly visitors increased 72% MoM.

  • Jan 25, 2025

    Monthly visitors grew 167% MoM, reaching 4K.

Partner Therapeutics Filings

Explore SEC and related filing metadata, where available.

Partner Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Partner Therapeutics's valuation, stock price, and market status.

Is Partner Therapeutics a public or private company?

Partner Therapeutics is a private company.

What is the current stock price of Partner Therapeutics?

Partner Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Partner Therapeutics worth (valuation)?

Valuation information for Partner Therapeutics is not publicly available.

Can I buy Partner Therapeutics stock?

Partner Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Partner Therapeutics's last funding round?

Partner Therapeutics's most recent funding round was Grant on February 17, 2022.

Who are the main investors in Partner Therapeutics?

Key investors in Partner Therapeutics include Perceptive Advisors.

Will Partner Therapeutics IPO soon?

No public IPO plans have been announced for Partner Therapeutics.

How can I track Partner Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Partner Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLexington, Massachusetts
Employee Range148
Year Founded2017
Last FundingFeb 17, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?